Status:
COMPLETED
Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors
Lead Sponsor:
OSI Pharmaceuticals
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.
Eligibility Criteria
Inclusion
- 18 years of age or older
- Advanced and/or metastatic solid tumor for which no effective therapy is available
- ECOG performance status 0-2
- Adequate bone marrow, hepatic and renal function
Exclusion
- Patients with active or uncontrolled infections
- Neurotoxicity \>= Grade 2
- Symptomatic brain metastases which are not stable
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
End Date :
December 1 2004
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00116896
Start Date
June 1 2003
End Date
December 1 2004
Last Update
January 21 2009
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt Universtiy Medical Center
Nashville, Tennessee, United States, 37232-6307
2
Institute for Drug DevelopmentCancer Therapy & Research Center
San Antonio, Texas, United States, 78229